J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, H.

DRUG INTERACTIONS

Population-Based Assessments of Clinical Drug-Drug Interactions: Qualitative Indices or Quantitative Measures?

Honghui Zhou, PhD, FCP

From Pharmacokinetics, Modeling & Simulation, Clinical Pharmacology & Experimental Medicine, Centocor Research & Development, Malvern, Pennsylvania.

Population-based assessments of drug-drug interactions have become more common since the introduction and acceptance of the population pharmacokinetic approach. Unlike traditional methods, population-based studies provide clinically relevant results that can be applied directly to a target patient population. Furthermore, population-based studies do not demand the traditional requirements of intensive pharmacokinetic sampling, rigorous inpatient stays, or stringent assessment schedules. As such, the population-based approach can effectively be used to confirm known drug-drug interactions and further characterize anticipated interactions. A prospectively designed analysis can also reveal drug-drug interactions that might otherwise have gone undetected with traditional methods. Ultimately, these results could help to alleviate clinicians' concerns about using widely marketed drugs in combination therapies and also reduce patients' risk of experiencing unacceptable side effects. This article intends to provide a balanced overview of the population-based approach and its merits, drawbacks, and potential utility in the assessment of drug-drug interactions during clinical drug development.

Key Words: opulation-based • drug-drug interaction • nonlinear mixed-effect modeling

Address for reprints: Honghui Zhou, PhD, FCP, Pharmacokinetics, Modeling & Simulation, Clinical Pharmacology & Experimental Medicine, Centocor Research & Development, 200 Great Valley Parkway, Malvern, PA 19087.




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
C. Hu and H. Zhou
An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis
J. Clin. Pharmacol., July 1, 2008; 48(7): 812 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson, W. Xu, H. M. Davis, and H. Zhou
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
J. Clin. Pharmacol., June 1, 2008; 48(6): 681 - 695.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. Seitz and H. Zhou
Pharmacokinetic Drug-Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check
J. Clin. Pharmacol., September 1, 2007; 47(9): 1104 - 1118.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology